Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.47 |
| ▸ | EGFR | P00533 | 7/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.39 |
| ▸ | LIPE | Q05469 | 1/20 | 0.38 |
| ▸ | TNNI3K | Q59H18 | 2/20 | 0.38 |
| ▸ | KDR | P35968 | 3/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | FLT3 | P36888 | 1/20 | 0.37 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL389969 | 0.88 | GPR119 (0.63) | GPR119EGFRCYP2C9 | |
| SCHEMBL4719890 | 0.83 | GPR119 (0.49) | GPR119EGFRTNNI3KKDRCDK2 | |
| SCHEMBL391663 | 0.78 | GPR119 (0.63) | GPR119CYP2C9 | |
| SCHEMBL13685341 | 0.78 | GPR119 (0.53) | GPR119EGFRERBB2CYP2C9CDK2 | |
| SCHEMBL390190 | 0.76 | GPR119 (0.60) | GPR119CYP2C9 | |
| SCHEMBL1837819 | 0.74 | KDM5B (0.41) | GPR119EGFRCDK2FLT3CDK6 | |
| SCHEMBL4723209 | 0.73 | GPR119 (0.49) | GPR119EGFRKDRCYP2C9CDK2 | |
| SCHEMBL5048945 | 0.73 | GPR119 (0.57) | GPR119EGFRERBB2KDRCDK2 | |
| SCHEMBL5046473 | 0.73 | GPR119 (0.46) | GPR119EGFREPHX2ERBB2CDK2 | |
| SCHEMBL3866032 | 0.73 | GPR119 (0.48) | GPR119EGFRERBB2CDK2FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2004157-B1 | USE OF GPR119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS, AS WELL AS COMBINATION THERAPY RELATING THERETO | ARENA PHARM INC (US) | 2011-01-12 | — | — | EP | disclosed |
| EP-2253311-A2 | Use of GPR119 receptor agonists for increasing bone mass and for treating osteoporosis, as well as combination therapy relating thereto | Arena Pharmaceuticals, Inc. (US) | 2010-11-24 | — | — | EP | disclosed |
| EP-2004157-A2 | USE OF GPR119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS, AS WELL AS COMBINATION THERAPY RELATING THERETO | Arena Pharmaceuticals, Inc. (US) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007120702-A2 | USE OF GPR119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS, AND COMBINATION THERAPY RELATING THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2007-10-25 | — | — | WO | disclosed |